anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Catheter-related bloodstream infections (CRBSIs) in patients receiving home parenteral nutrition (HPN) for chronic intestinal failure (CIF) are associated with significant morbidity and financial costs. Taurolidine is associated with a reduction in bloodstream infections, with limited information on the cost-effectiveness as the primary prevention. This study aimed to determine the cost-effectiveness of using taurolidine-citrate for the primary prevention of CRBSIs within a quaternary hospital.
METHODS: All patients with CIF receiving HPN were identified between January 2015 and November 2022. Data were retrospectively collected regarding patient demographics, HPN use, CRBSI diagnosis, and use of taurolidine-citrate. The direct costs associated with CRBSI-associated admissions and taurolidine-citrate use were obtained from the coding department using a bottom-up approach. An incremental cost-effective analysis was performed, with a time horizon of 4 years, to compare the costs associated with primary and secondary prevention against the outcome of cost per infection avoided.
RESULTS: Forty-four patients received HPN within this period. The CRBSI rates were 3.25 infections per 1000 catheter days before the use of taurolidine-citrate and 0.35 infections per 1000 catheter days after taurolidine-citrate use. The incremental cost-effectiveness ratio indicates primary prevention is the weakly dominant intervention, with the base case value of $27.04 per CRBSI avoided. This held with one-way sensitivity analysis.
CONCLUSION: Taurolidine-citrate in the primary prevention of CRBSIs in patients with CIF receiving HPN is associated with reduced hospital costs and infection rates.
INTRODUCTION: Anemia is frequent in patients undergoing replacement therapy for kidney failure. Anemia in the pre- and post-transplantation period might be related to kidney transplant outcomes. The current study therefore sought to assess the relationship between anemia, delayed allograft function (DGF), chronic kidney allograft dysfunction (CAD), and death from any cause following kidney transplantation from a deceased donor.
METHODS: This was a retrospective study with 206 kidney transplant patients of deceased donors. We analyzed deceased donors' and kidney transplant patients' demographic data. Moreover, we compared biochemical parameters, anemia status, and medicines between DGF and non-DGF groups. Afterward, we performed a multivariate analysis. We also evaluated outcomes, such as CAD within one year and death in ten years.
RESULTS: We observed a lower frequency of pre-transplant hemoglobin concentration (Hb) but higher frequency of donor-serum creatinine and red blood transfusion within one week after transplantation in the group with DGF. In addition, there was an independent association between Hb concentration before transplantation and DGF [OR 0.252, 95%CI: 0.159-0.401; p < 0.001]. There was also an association between Hb concentration after six months of kidney transplantation and both CAD [OR 0.798, 95% CI: 0.687-0.926; p = 0.003] and death from any cause.
CONCLUSION: An association was found between pre-transplantation anemia and DGF and between anemia six months after transplantation and both CAD and death by any cause. Thus, anemia before or after transplantation affects the outcomes for patients who have undergone kidney transplantation from a deceased donor.
The retrospective phase will collect data from previous TAVR procedures completed between February 2019 and October 1, 2021. Data from up to 200 patient charts will be collected using the Society of Thoracic Surgeons/American College of Cardiology that is maintained by the CMH Cardiology Department. The population will be de-identified as the purpose is to obtain descriptive information from the medical records to utilize for propensity match scoring.
PURPOSE:To obtain a useful analgesic agent, containing a double-enkephalin (biphalin) compound or salt thereof and having naloxone reversible antitussive and analgesic effects without affecting respiration. CONSTITUTION:An antitussive agent containing a compound expressed by the formula or salt thereof as an active ingredient. The compound expressed by the formula is obtained by a method for synthesizing amino acids. For example, the compound is obtained by using benzyloxycarbonyl-Phe-4-nitrophenyl and passing through benzyloxycarbonyl-Phe-NH-NH2,(benzyloxycarbonyl-Phe-NH-)2-, (HBr-Phe-NH-)2- and (tetra-butyloxycarbonyl-Tyr-D-Ala-Gly-Phe-NH-)2. The afore-mentioned antitussive agent is used in a dose of normally 2-300mg, preferably 5-100 mg as the active ingredient per day for an adult. The unit dose contains 2-20mg compound expressed by the formula or salt thereof.
Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
BACKGROUND: TGF (transforming growth factor)-β pathway is central to blood-brain barrier development as it regulates cross talk between pericytes and endothelial cells. Murine embryos lacking TGFβ receptor Alk5 (activin receptor-like kinase 5) in brain pericytes (mutants) display endothelial cell hyperproliferation, abnormal vessel morphology, and gross germinal matrix hemorrhage-intraventricular hemorrhage (GMH-IVH), leading to perinatal lethality. Mechanisms underlying how ALK5 signaling in pericytes noncell autonomously regulates endothelial cell behavior remain elusive.
METHODS: Transcriptomic analysis of human brain pericytes with ALK5 silencing identified differential gene expression. Brain vascular cells isolated from mutant embryonic mice with GMH-IVH and preterm human IVH brain samples were utilized for target validation. Finally, pharmacological and genetic inhibition was used to study the therapeutic effects on GMH-IVH pathology.
RESULTS: Herein, we establish that the TGFβ/ALK5 pathway robustly represses ANGPT2 (angiopoietin-2) in pericytes via epigenetic remodeling. TGFβ-driven SMAD (suppressor of mothers against decapentaplegic) 3/4 associates with TGIF1 (TGFβ-induced factor homeobox 1) and HDAC (histone deacetylase) 5 to form a corepressor complex at the Angpt2 promoter, resulting in promoter deacetylation and gene repression. Moreover, murine and human germinal matrix vessels display increased ANGPT2 expression during GMH-IVH. Isolation of vascular cells from murine germinal matrix identifies pericytes as a cellular source of excessive ANGPT2. In addition, mutant endothelial cells exhibit higher phosphorylated TIE2 (tyrosine protein kinase receptor). Pharmacological or genetic inhibition of ANGPT2 in mutants improves germinal matrix vessel morphology and attenuates GMH pathogenesis. Importantly, genetic ablation of Angpt2 in mutant pericytes prevents perinatal lethality, prolonging survival.
CONCLUSIONS: This study demonstrates that TGFβ-mediated ANGPT2 repression in pericytes is critical for maintaining blood-brain barrier integrity and identifies pericyte-derived ANGPT2 as an important pathological target for GMH-IVH.
In recent years, with the improvement of living standards and lifestyle changes, the incidence of type II diabetes is increasing, and T2DM has become a worldwide disease that seriously endangers people ' s health. When patients with diabetes in the middle and late, the condition is often irreversible, and early if effective treatment, help to improve the condition in a timely manner, delay the development of the disease process. Therefore, early diagnosis and treatment is the key to prevention and treatment of diabetes. Years of studies have shown that insulin resistance and β-cell dysfunction are the two major mechanisms of type II diabetes. Previous studies on the pathogenesis of type II diabetes mostly focused on insulin resistance, and there are few studies on β-cell dysfunction. Therefore, the study of islet β-cell dysfunction is extremely important. According to previous studies, the investigator found that although insulin resistance exists in type II diabetes, also exists to the same extent in many people who do not have diabetes. These people may have or do not have metabolic syndrome. Therefore, insulin resistance alone cannot be the decisive pathogenic factor of type II diabetes, and the increasing facts indicate that the abnormality of islet cells, especially islet β cells, may be the central link in the pathogenesis of type II diabetes. Obviously, insulin resistance is the initiating factor of type II diabetes, and the normal function of islet β cells is the determinant of whether type II diabetes occurs : the occurrence of insulin resistance initiates the pathogenesis of type II diabetes, but if the islet β cells can maintain its compensatory ability, type II diabetes will not occur. Once its compensatory ability decreases, type II diabetes gradually occurs. Therefore, islet β cell dysfunction is the key to the pathogenesis of type II diabetes. Exploring the harmful factors that impair β-cell function is critical for early prevention and treatment of diabetes.
All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
X-linked creatine transporter deficiency is caused by hemizygous or heterozygous pathogenic variants in SLC6A8 that cause neuropsychiatric symptoms because of impaired uptake of creatine into tissues throughout the body. Small cohorts have suggested that supplementation of creatine, arginine, and glycine can stop disease progression in males, but only six cases of supplementation in females have been published. Here, we present a female with a de-novo pathogenic SLC6A8 variant who had ongoing weight loss, mild intellectual disability, and neuropsychiatric symptoms. Magnetic resonance spectroscopy of the brain showed reduced creatine on all acquired spectra. The patient was started on creatine-monohydrate, l -arginine, and l -glycine supplementation, and she had significant symptomatic improvement within the following 3 weeks. After 8 months of supplementation, magnetic resonance spectroscopy showed improved creatine concentrations with normalizing semiquantitative ratios with other brain metabolites. Current data supports clinicians trialing creatine, arginine, and glycine supplements for female patients with creatine transporter deficiency.
Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
The invention discloses a preparation method for a low-polymerization-shrinkage-ratio dental composite resin material, and belongs to the technical field of dental restoration materials. The material compositions are an acrylate monomer, filling materials and an initiator. The method comprises preparation of a composition filling material and preparation of the composite resin material. The first step comprises adding a nanometer silicon powder into a disperse medium for pre-dispersing, and adding other filling materials; and mixing with a part of a mixture of the acrylate monomer and the initiator, steaming out the disperse medium, performing illumination solidification, and crushing to obtain the composite filling material. The second step comprises adding the composite filling material into the disperse medium for pre-dispersing; adding the residual mixture of the acrylate monomer and the initiator, stirring, mixing, steaming out the disperse medium so as to obtain the dental composite resin material. The usage mass ratio of the mixture of the acrylate monomer and the initiator in the first step and in the second step is 65-85:15-35. By using the pre-coating method divided into two steps, the polymerization shrinkage of the dental composite resin material is obviously reduced, and the pre-dispersing processing enables the filling materials and the composite filling material to be uniformly dispersed in the monomer.
The human gut microbiota is home to a diverse collection of microorganisms that has co-evolved with the host immune system in which host-microbiota interactions are essential to preserve health and homeostasis. Evidence suggests that the perturbation of this symbiotic host-microbiome relationship contributes to the onset of major diseases such as chronic inflammatory diseases including Inflammatory Bowel Disease. The host glycocalyx (repertoire of glycans/sugar-chains at the surface of gut mucosa) constitutes a major biological and physical interface between the intestinal mucosa and microorganisms, as well as with the host immune system. Glycans are an essential niche for microbiota colonization and thus an important modulator of host-microorganism interactions both in homeostasis and in disease. In this review, we discuss the role of gut mucosa glycome as an instrumental pathway that regulates host-microbiome interactions in homeostasis but also in health to inflammation transition. We also discuss the power of mucosa glycosylation remodelling as an attractive preventive and therapeutic strategy to preserve gut homeostasis.
A method for producing a vaccine for use in immunotherapy of cancer is provided. An exosome cannot be fused with dendritic cells if its exosome is left for a certain period of time or more even at room temperature. Therefore, it is necessary to perform the heat treatment under conditions that maintain the exosome membrane structure while promoting peptidation of the protein, and the conditions are 56 ℃. or less and 30 minutes or less. At higher temperature conditions, the protein is denatured and cannot maintain antigenicity. Therefore, exosomes (Exosome) separated from cancer cells or body fluids such as blood of 
a cancer patient are heated at 56 ℃. or lower and for 30 minutes or lower to promote inactivation of protein enzymes in the exosomes, Deactivates proteolytic and lipolytic enzymes. Next, this exosome is introduced or co-cultured into dendritic cells derived from the blood of a cancer patient or a healthy subject.
Bilateral transmuscular QL block will be performed under ultrasound-guidance. Twenty mililiter of 0.375% ropivacaine will be injected to each side.
Low back pain (LBP) is a prevalent and costly condition globally, prompting the need to identify risk factors for effective management. Lower extremity misalignment plays a crucial role in the incidence of LBP. Therefore, we aimed to investigate the current evidence on a link between lower limb alignment and LBP, enhancing the understanding of this relationship. We searched four databases, including PubMed, Embase, Web of Science, and Scopus, up to September 2024. Inclusion criteria encompassed studies related to LBP and lower limb alignment, with eligible study types including case-control, cohort, and cross-sectional studies, all written in English. Two authors independently screened and assessed the methodological quality of the retrieved papers using the Downs and Black quality assessment checklist. Data of interest including study design, age, sample size, cases, association, and P-value were extracted from the included studies. Mean differences and 95% confidence intervals (CI) were calculated with random effects model in RevMan version 5.4. Thirteen articles evaluating lower limb alignment in individuals with LBP were included (102,359 participants in total). The meta-analysis results demonstrated that increased pronation with strong evidence(p = 0.02), increased hip internal rotation with moderate evidence, and increased knee internal rotation with limited evidence are associated with an increased risk of LBP. Overall, while some studies supported a relationship between lower limb alignment and LBP, the heterogeneity of study designs and methodological limitations hindered drawing a definitive conclusion. Future research should emphasize prospective cohort studies, incorporating objective measures of lower extremity alignment and standardized outcome measures.
EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
Excessive glucocorticoid (GC) action is linked to various metabolic disorders. Recent findings suggest that disrupting skeletal GC signaling prevents bone loss and alleviates metabolic disorders in high-fat diet (HFD)-fed obese mice, underpinning the neglected contribution of skeletal GC action to obesity and related bone loss. Here, we show that the elevated expression of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), the enzyme driving local GC activation, and GC signaling in osteoblasts, are associated with bone loss and obesity in HFD-fed male mice. Osteoblast-specific 11β-HSD1 knockout male mice exhibit resistance to HFD-induced bone loss and metabolic disorders. Mechanistically, elevated 11β-HSD1 restrains glucose uptake and osteogenic activity in osteoblast. Pharmacologically inhibiting osteoblastic 11β-HSD1 by using bone-targeted 11β-HSD1 inhibitor markedly promotes bone formation, ameliorates glucose handling and mitigated obesity in HFD-fed male mice. Taken together, our study demonstrates that osteoblastic 11β-HSD1 directly contributes to HFD-induced bone loss, glucose handling impairment and obesity.
Participants will receive JNJ-88998377 at a selected starting dose. Subsequent dose levels and schedules will be selected based on the review of all available data to establish recommended Phase 2 dose (RP2D).
The Endoscopic Cap Electrode (ECE50) has been designed for the delivery of electrostimulation to selected laryngeal muscles. The primary objective of this registry is to retrieve real-life data on the safety and performance of the Endoscopic Cap in medical routine. Subject's participation will last a maximum of 2 hours. Upon successful conclusion of the screening session starts the testing session of the ECE50. The ECE50 has been designed to be placed on the top of a videoendoscope for the delivery of electrostimulation to the laryngeal region. The stimulation and reaction of the muscles can provide information about the presence and type of dysfunctions and thus influence the treatment procedure. Being a registry a collection of records generated within routine medical procedures with a medical device approved for the EU market, it does not pose additional risks for the patients participating in it.
The invention discloses a method for repeatedly heating cancer cells through magnetic electrostatic spinning fibers. 50 nm magnetic iron oxide nano-particles (IONPs) can be loaded through an electrostatic spinning nano-fiber web. An alternating magnetic field can be applied on the environment through the high loading capacity of electrostatic spinning, and therefore heating capacity is remarkably improved. Besides, the magnetic fibers can be repeatedly used without reducing the heating capacity of the magnetic fibers or reducing the release content of the magnetic iron oxide nano-particles. By functionally modifying the fiber surfaces through collagen, ovarian cancer cells can well adhere to the fibers, and the cancer cells adhering to the fibers can be killed within minutes by adjusting temperature in the fiber web magnetic field area. Compared with a method for heating and killing cancer cells through a hot water bath, the method is more effective. Through the fiber web, the content of the loaded magnetic iron oxide nano-particles can be well controlled, and in-vivo positioning can be achieved through MRI.
A process is provided for the production of a substantially crystallographically pure polymorphic form of cimetidine having the structural formula Such cimetidine is characterized by an infra red spectrum (1% KBr disc) having very strong, broad peaks at 1400 and 1385 cm-1, a strong, sharp peak at 1205 cm-1 and a medium-sharp peak at 1155 cm01 and having no peak at 1180 cm-1. The process includes dissolving cimetidine in a hot, nonaqueous solvent, e.g., acetonitrile, acetone, methylisobutylketone, toluene or a lower alkanol. The resultant solution is cooled with sufficient agitation to ensure efficient heat transfer to yield a suspension of cimetidine A in the solvent. The suspension is now characterized by good handling properties. Finally, the cimetidine A is separated off. Suchcimetidine A is more easily obtainable in a crystallographically pure state. It is also slightly more water soluble than either of the other forms, and preferably has a rate of dissolution at 25.degree.C. from the flat sur-face of a standard compressed disc of at least 0.20 mg/min/cm2. A further advantage is that such cimetidine A is rather more easy to handle, particularly in large scale operations, such as centrifugation.
If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
The present invention relates to a pure Chinese medicine preparation for curing angiitis and its preparation method. Its preparation composition includes 16 Chinese medicinal materials of root of doubleteeth pubescent angelica, Chinease taxillus, sweet potato, salvia root, saffron, achyranthes root, ginseng, astragalus root and others. Its preparation method includes the following steps: selecting materials, washing, drying at 100-120 deg.C in earthenware pot, cooking, sterilizing for 30 min. by using UV-ray, proportioning according to prescription, pulverizing to 120 meshes, mixing and stirring, sealing in container, when it is used, packaging and bagging so as to obtain the invented product. Said invention also provided its method for taking medicine. It has no toxic effect, and its cure rate is up to 98%.
Hair and other keratinous materials are dyed by first impregnating with an aqueous solution of 5 : 6-dihydroxy-indole at a pH of at most 7 for 5-60 minutes at room temperature, then blotting off excess solution, and finally applying an aqueous solution capable of inducing oxidation of the dihydroxyindole. The dihydroxyindole solution may be acidified with an inorganic acid or an organic acid such as formic, acetic or monochloracetic acid, and water-miscible solvents such as ethyl alcohol, isopropyl alcohol, glycols and glycol ethers, may also be added, as also may small amounts of reducing agents, such as alkali metal sulphites, bisulphites and hydrosulphites, and of sequestering agents, such as ethylenediamine tetracetic acid or a salt thereof.  Oxidation may be effected with the ambient air, in which case the oxidation-inducing solution may contain ammonia, a basic ammonium salt or an amine together with, if desired, an oxidation catalyst, such as cobalt or manganese sulphate or lactate.  Alternatively, the oxidation-inducing solution may contain an oxidizing agent such as hydrogen peroxide, an alkali metal or ammonium iodate, periodate or persulphate, or an alkali metal salt of an N-chlorinated derivative of a sulphonamide.  The developing solution may also contain electrolytes such as sodium chloride or sulphate.  The dihydroxy indole may be employed in association with di- or trihydric phenols as additional colour bases. Numerous examples are given.  Specification 797,174 is referred to.